Insider Cluster (5 insiders) ·Filed Feb 23, 2026

KALV

KalVista Pharmaceuticals, Inc.
BEARISH
Impact 6/10
Horizondays Processed7mo ago
Insider cluster: 5 insiders, $0.4M total
Actionable Insight ▼ Bearish

Traders should monitor for potential downward pressure on KALV shares, especially if this selling continues in the next reporting window. The uniformity and timing suggest pre-arranged 10b5-1 plans, but the concentration of C-suite selling may signal lack of near-term conviction.

DirectionBearish
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
KALV ▲ +71.98% at T+60d
SHORT call ✗ call lost -71.98% · α vs SPY -63.73% · entry $15.56 → $26.76
Entry anchored
Feb 20, 03:59 PM ET
via exchange tick
T+1d
+1.35%
call -1.35% · α -0.61%
$15.77
settled 7mo ago
T+5d
+3.21%
call -3.21% · α -2.59%
$16.06
settled 7mo ago
T+20d
+6.68%
call -6.68% · α -10.63%
$16.60
settled 7mo ago
T+60d
+71.98%
call -71.98% · α -63.73%
$26.76
settled 5mo ago

Price Chart

Loading chart...

Executive Summary

Seven executives at KalVista Pharmaceuticals, including the CEO, CFO, CMO, CDO, and CCO, exercised stock options and sold shares in the open market over a 7-day period. The total value of shares sold was approximately $396,600, with all sales occurring at $15.5668 per share. The transactions appear to be part of a coordinated post-exercise selling activity following option exercises.

Key Financial Metrics

Direction
selling
Total Value
$396.6K
Insiders
5

Key Facts

  • CEO Palleiko sold 10,034 shares for $156,197; exercised 23,250 shares prior to sale
  • All five C-suite executives exercised in-the-money stock options between Feb 21–23
  • Total open-market sales: 25,477 shares sold for $396,600 across four days
  • Sales were executed at a uniform price of $15.5668, indicating planned trades
  • No insider purchases were observed in the cluster

Financial Impact

$396,600 in insider selling over 7 days

insider ownershipmarket sentimentshareholder dilution (potential)

Risk Factors

  • Perception of insider pessimism despite possible pre-arranged plans
  • Potential for follow-on selling if 10b5-1 plans are ongoing
  • Lack of offsetting insider buying during a period of material activity

Market Snapshot

Exchange
Nasdaq

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CONTEXT: Insider Cluster Data (13 trades, 7d window)cluster-KALV-1772017264193
12 reports for KALV
Performance horizon
60% Hit rate 3 of 5 directional calls best @ T+5▲ +4.15%Apr 17, 2026
Filters
Rows
Reports for KALV — sortable, filterable
TypeNow
Jun 22, 2026
14w ago
15-12G
BEARISH ★ 7/10
—awaiting T+1——
Jun 17, 2026
15w ago
EFFECT
NEUTRAL ★ 3/10
$27.00 awaiting T+1awaiting T+1——
Jun 11, 2026
16w ago
8-K
NEUTRAL ★ 5/10
$26.99 awaiting T+1awaiting T+1——
Jun 11, 2026
16w ago
Institutional Cluster
NEUTRAL ★ 2/10
$27.00 $27.00· 0.00%▼ −0.54%—
May 19, 2026
19w ago
Insider Cluster
BEARISH ★ 5/10
$26.81 $26.77▲ +0.15%▲ +0.34%—
May 19, 2026
19w ago
Insider Cluster
NEUTRAL ★ 2/10
$26.81 $26.77▼ −0.15%▼ −0.34%—
Apr 29, 2026
22w ago
8-K
BULLISH ★ 8/10
$26.67 $26.66▼ −0.04%▼ −1.06%—
Apr 17, 2026
24w ago
Insider Cluster
BEARISH ★ 6/10
$20.48 $20.87▼ −1.90%▼ −2.10%—
Feb 23, 2026
31w ago
Insider Cluster
BEARISH ★ 6/10
$15.56 $15.77▼ −1.35%▼ −0.61%—
Feb 23, 2026
31w ago
Insider Cluster
BEARISH ★ 7/10
$15.56 $15.77▼ −1.35%▼ −0.61%—
Showing 10 of 12

US Market Status

Market Open — Closes in 2h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Feb 25, 2026